10-Q: Pulmonx Reports Q2 2026 Results, Revenue Declines

Pulmonx Corporation filed its Form 10-Q for the quarter ended June 30, 2026, reporting a decrease in revenue and a net loss, while also detailing debt financing and operational updates.

Summary

• Pulmonx Corporation reported a net loss of $10.1 million for the three months ended June 30, 2026, compared to a net loss of $15.2 million in the same period of 2025.
• Revenue for the three months ended June 30, 2026, decreased by 4.6% to $22.8 million, compared to $23.9 million for the same period in 2025.
• Gross margin improved to 78.0% for the three months ended June 30, 2026, up from 72.1% in the prior year period.
• Selling, general, and administrative expenses decreased by 18.5% to $21.8 million for the three months ended June 30, 2026.
• As of June 30, 2026, the company had $55.8 million in cash and cash equivalents and $37.5 million in outstanding debt.
• The company repaid its CIBC Loan and drew down on its Perceptive Loan during the period.
• The company is focused on expanding its commercial operations in the United States and internationally.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a mixed to slightly negative filing due to declining revenues and continued net losses, despite improvements in gross margin and reduced operating expenses.

Positives

• Gross margin improved to 78.0% for the three months ended June 30, 2026, up from 72.1% in the prior year period.
• Selling, general, and administrative expenses decreased by 18.5% to $21.8 million for the three months ended June 30, 2026.
• Research and development expenses decreased slightly by 5.1% to $5.0 million for the three months ended June 30, 2026.
• The company secured the renewal of its Chinese registration certificate in June 2026, aiming to restart commercial activity in the region.

Negatives

• Revenue decreased by 4.6% to $22.8 million for the three months ended June 30, 2026, compared to $23.9 million in the prior year period.
• Net loss for the three months ended June 30, 2026, was $10.1 million, a widening from the previous quarter's net loss of $13.7 million.
• Interest expense increased by 52.4% to $1.2 million for the three months ended June 30, 2026, primarily due to higher rates on the Perceptive Loan.
• Interest income decreased by 54.5% to $0.3 million, reflecting a lower balance of cash and cash equivalents.

Risks

• The company has a history of significant net losses and expects to continue incurring losses, with no guarantee of future profitability.
• Reliance on a single product, the Zephyr Valve, for most revenue, with limited indications, poses a significant risk if commercialization falters.
• Adoption of the Zephyr Valve by hospitals, physicians, and patients is critical, and any unwillingness to change current practices could negatively impact the business.
• Failure to obtain and maintain adequate third-party reimbursement for its solutions could severely hinder commercial success.
• The company has limited experience in marketing and selling its solution and faces manufacturing risks that could affect production and gross margins.
• The company expects to continue to require substantial additional capital, and future financing may not be available on acceptable terms or at all.
• Product liability claims, including those related to complications like pneumothorax or death, could arise and negatively impact the business.
• The company is subject to extensive government regulation and oversight, and failure to comply could result in significant penalties.

Future Outlook

The company expects to continue to incur net losses for the next several years and anticipates requiring substantial additional capital, potentially through future equity and debt financings. Management believes current cash and cash equivalents are sufficient for at least the next 12 months of planned operations.

Management Comments

• We are focused on restarting commercial activity in the region for the remainder of this year and anticipate resuming shipments to our Chinese distributor by early next year.
• Management believes that the Company's existing cash and cash equivalents will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed consolidated financial statements.

Industry Context

StockSavvy.ai notes that Pulmonx operates in the competitive medical technology sector, specifically focusing on treatments for severe emphysema. The company's performance is influenced by adoption rates, reimbursement policies, and ongoing R&D for next-generation products, mirroring trends seen in other specialized medical device companies.

Management Changes

Legal Proceedings

• The company settled a civil investigative demand (CID) from the U.S. Department of Justice (US DOJ) related to an investigation under the False Claims Act. The Qui Tam Action was dismissed on December 22, 2025, following a settlement agreement.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees' stock options may be affected by stock price volatility.
• Customers (hospitals and distributors) may face increased costs if the company passes on higher manufacturing or operational expenses.
• Creditors may be impacted by the company's ongoing net losses and need for future financing.

Next Steps

• Restart commercial activity in China and resume shipments to the Chinese distributor by early next year.
• Continue to make significant investments in the sales and marketing organization in the United States, Europe, and Asia Pacific.
• Continue to invest in research and development efforts for next-generation products and support future regulatory submissions.
• Continue to work to broaden coverage by private third-party payor policies.

Key Dates

Recommendation

While the company shows some operational improvements like increased gross margin and reduced SG&A, the continued revenue decline and net losses, coupled with the need for future capital raises, suggest a cautious approach. The positive developments in China and the new debt financing provide some stability, but the path to profitability remains uncertain.

Keywords

Pulmonx, Zephyr Valve, Emphysema, COPD, Medical Technology, Interventional Pulmonology, Endobronchial Valve, Healthcare